All articles by Swagath Bandhakavi
Swagath Bandhakavi
Roche says positive Phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members
PharmaJet and Scancell partner on needle-free DNA vaccine for melanoma
Under the agreement, Scancell will utilise the Stratis system for both clinical development and future commercialisation of its melanoma DNA vaccine
BeiGene’s Tevimbra gets Israeli approval for oesophageal squamous cell carcinoma
The approval makes Tevimbra available as a monotherapy for those suffering from the disease
Nura Bio closes Series A financing with $68m in new funds
Company announces successful completion of Phase 1 study of NB-4746, Nura Bio’s brain-penetrant SARM1 inhibitor
Debiopharm partners with WhiteLab Genomics to enhance drug targeting in oncology
Debiopharm will utilise WhiteLab Genomics’ AI platform to identify agents that boost the targeting capabilities of non-viral vectors in oncology
FDA grants RMAT status to Poseida’s P-BCMA-ALLO1 for relapsed/refractory multiple myeloma
P-BCMA-ALLO1 is an investigational allogeneic CAR-T cell therapy that is presently in Phase 1/1b clinical trials
Novartis’ Kisqali reduces risk of recurrence by 28.5% in broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease
Dupixent gains FDA approval for expanded use in adolescents with CRSwNP
The approval of Dupixent for this indication is supported by data from the Phase 3 SINUS-24 and SINUS-52 clinical trials
Pfizer’s Braftovi and Mektovi show long-term benefit in NSCLC Phase 2 trial
The longer-term follow-up results from the PHAROS clinical trial showed encouraging outcomes for both treatment-naïve and previously treated patients
Japan approves CSL and Arcturus Therapeutics’ updated self-amplifying mRNA COVID-19 vaccine for protection against JN.1 strain
Approval underscores CSL and Arcturus Therapeutics’ commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health